SpringerProtocols: Abstract: Aqueous Formulation of Adjuvant-Active Nonionic Block Copolymers

Aqueous Formulation of Adjuvant-Active Nonionic Block Copolymers

By: Charles W. Todd², Mark J. Newman³

Abstract

Full Text

Download PDF (115K)

Despite the recent advances in vaccine technology, there is still a need for safe and effective adjuvants to potentiate the immune responses to subunit immunogens (1). Depending on the disease in question, the vaccine-induced protection may require either a predominantly antibody-mediated response, under the control of (T-helper lymphocyte) Th2-associated cytokines, typically interleukin-4, -5, and -10 (IL-4, -5, -10), or a predominantly cellular response, the Th1 type, characterized by cells producing IL-2, IL-12, and gammainterferon (γ-IFN), or some combination thereof (2,3). Ideally, a vaccine delivery

Affiliation(s): (2) Vaxcel, Inc., Norcross, GA
(3) Epimmune, San Diego, CA

Book Title: Vaccine Adjuvants: Preparation Methods and Research Protocols

Series: Methods in Molecular Medicine | Volume: 42 | Pub. Date: Apr-15-2000 | Page Range: 121-136 | DOI: 10.1385/1-59259-083-7:121

Subject: Immunology

References

Download References

1.	Lawrence, D. N., Goldenthal, K. L., Boslego, J. W., Chandler, D. K. F., and La Montagne, J. R. (1995) Public health implications of emerging vaccine technologies, in Vaccine Design: The subunit and adjuvant approach (Powell, M. F. and Newman, M. J., eds.), Plenum, New York, pp. 43–60.

2.	Scott, P., Pearce, E., Cheever, A. W., Coffman, R. L., and Sher, A. (1989) Role of cytokines and CD4+T-cell subsets in the regulation of parasitic immunity and disease. Immunol. Rev. 112, 161–182.

3.	Seder, R. A. and Paul, W. E. (1994) Acquisition of lymphokine-producing pheno-type by CD4+T cells. Ann. Rev. Immunol. 12, 635–673.

4.	Hunter, R. L., Strickland, F., and Kezdy, F. (1981) The adjuvant activity of non-ionic block copolymer surfactants. I. The role of hydrophile-lipophile balance. J. Immunol. 127, 1224–1250.

5.	Hunter, R. L. and Bennet, B. (1984) The adjuvant activity of nonionic block copolymer surfactants. II. Antibody formation and inflammation related to the structure of triblock and octablock copolymers. J. Immunol. 133, 3167–3175.

6.	Hunter, R. L., Olsen, M. R., and Bennet, B. (1995) Copolymer adjuvants and Titermax®, in The theory and practical application of adjuvants (Stewart-Tull, D. E. S., ed.), Wiley, London, UK, pp. 51–94.

7.	Newman, M. J., Todd, C. W., Lee, E. M., Balusubramanian, M., Didier, P. J., and Katz, J. M. (1997) Increasing the immunogenicity of a trivalent influenza virus vaccine with adjuvant-active nonionic block copolymers for potential use in the elderly. Mech. Ageing Develop. 93, 189–203.

8.	Todd, C. W., Pozzi, L.-A. M., Guarnaccia, J. R., Balusubramanian, M., Henk, W. G., Younger, L. E., and Newman, M. J. (1997) Development of an adjuvant-active nonionic block copolymer for use in oil-free subunit vaccine formulations. Vaccine 15, 564–570.

9.	Todd, C. W., Lee, E., Balusubramanian, M., Shah, H., Henk, W. G., Younger, L. E., and Newman, M. J. (1997) Systematic development of a block copolymer adjuvant for trivalent influenza virus vaccine, in Modulation of the Immune Response to Vaccine Antigens (Brown, F. and Haaheim, L. R., eds.), Dev. Biol. Stand. 92, Karger, Basel, pp. 343–353.

10.	Triozzi, P. L., Stevens, V. C., Aldrich, W., Powell, J., Todd, C. W., and Newman, M. J. (1997) Effects of a β-human chorionic gonadotrophin subunit immunogen administered in aqueous solution with a novel noninoic block copolymer adjuvant in patients with advanced cancer. Clinical Cancer Res.3, 2355–2362.

11.	Newman, M. J., Actor, J. K., Balusubramanian, M., and Jagannath, C. (1998) Use of nonionic block copolymers in vaccines and therapeutics. Critical Rev. Therap. Drug Carrier Sys. 15, 89–142.

12.	Hem, S. L. and White, J. L. (1995) Structure and properties of aluminum-containing adjuvants, in Vaccine Design: The subunit and adjuvant approach (Powell, M. F. and Newman, M. J., eds.), Plenum, New York, pp. 249–276.

13.	Kensil, C. R., Wu, J-Y., and Soltysik, S. (1995) Structural and immunological characterization of the vaccine adjuvant QS-21, in Vaccine Design: The subunit and adjuvant approach (Powell, M. F. and Newman, M. J., eds.), Plenum, New York, pp. 525–541.

14.	Reis e Sousa, C., Stahl, P. D., and Austyn, J. M. (1993) Phagocytosis of antigens by Langerhans cells in vitro. J. Exp. Med. 178, 509–519.

15.	Karlström, G., Carlsson, A., and Lindmann, B. (1990) Phase diagrams of nonionic polymer-water systems. Experimental and theoretical studies of the effects of surfactants and other cosolutes. J. Phys. Chem. 94, 5005–5015.

16.	Triozzi, P. L., Gonchour, D., Martin, E. W., Aldrich, W., Powell, J., Kim, J. A., et al. (1994) Clinical and immunological effects of a synthetic β-human chorionic gonadotrophin vaccine. Int. J. Oncol. 5, 1447–1454.

17.	Manetti, R., Parronchi, P., Guidizi, M. G., Piccinni, M.-P., Maggi, E., Trinchieri, G., and Romagnani, S. (1993) Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J. Exp. Med., 177 1199–1204.

18.	Seder, R. A., Gazzinelli, R. T., Sher, A., and Paul, W. E. (1993) Interleukin-12 acts directly on CD4+T cells to enhance priming for interferon gamma produc-136 tion and diminishes interleukin 4 inhibition of such priming. Proc. Natl. Acad. Sci. USA 90, 10,188–10,192.

19.	Swain, S. L., Weinberg, A. D., English, M., and Huston, G. (1990) IL-4 directs the development of Th2-like helper effectors. J. Immunol. 145, 3796–3806.

20.	Code of Federal Regulation 21 CRF 610.11 (1993) 46-48.

21.	United States Pharmacopeia 23, (1995) 41718-1719.

22.	United States Pharmacopeia 23, (1995) 1696-1697.

Comments (Loading...)

Post comment/View all comments